Alvotech Secures FDA Clean Slate on Reykjavik Facility, Boosts Biosimilar Credibility
Alvotech’s Reykjavik site cleared FDA inspection—no violations, VAI status, confirming robust manufacturing for future biosimilar launches.
2 minutes to read
ALVOTECH SA
Alvotech’s AVT80 PK Study Hits All Targets, Boosting Biosimilar Growth
Alvotech’s AVT80 PK study meets all primary endpoints, confirming biosimilarity to Entyvio and positioning the company for fast regulatory approvals and market entry.
2 minutes to read
Alvotech SA Makes Strategic Move with Nasdaq Stockholm Listing, Boosting Investor Confidence and Market Presence
Alvotech SA successfully lists on Nasdaq Stockholm, marking a strategic expansion and surge in investor confidence, as the biotech company continues to ride the wave of its robust performance in the biosimilar medicines sector.
2 minutes to read
FDA Approves SELARSDI™ as Interchangeable with Stelara®, a Milestone for Alvotech and Teva
The FDA has approved Alvotech’s biosimilar SELARSDI as interchangeable with Stelara, a major milestone for the biotech company and a significant step forward for the industry in terms of affordable treatment options.
3 minutes to read
Alvotech SA Faces Critical Financial Webcast Amid Rising Short Interest and Market Uncertainty
Alvotech SA is set to unveil its first-quarter financial results on May 8, 2025, amidst rising short interest and market uncertainty, with investors and analysts closely watching for clarity on the company’s future prospects.
2 minutes to read